公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2017 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study | Ahn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; CHIA-CHI LIN ; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG | The Lancet Respiratory Medicine | 81 | 67 | |
2008 | Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma | CHIA-CHI LIN ; YEONG-SHIAU PU ; CHIH-HUNG HSU ; Keng H.-Y.; ANN-LII CHENG ; CHIH-HSIN YANG | Urologic Oncology: Seminars and Original Investigations | 8 | 7 | |
2019 | ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non–small-cell lung cancer | Shaw A.T.; Solomon B.J.; Besse B.; Bauer T.M.; CHIA-CHI LIN ; Soo R.A.; Riely G.J.; Ignatius Ou S.-H.; Clancy J.S.; Li S.; Abbattista A.; Thurm H.; Satouchi M.; Camidge D.R.; Kao S.; Chiari R.; Gadgeel S.M.; Felip E.; Martini J.-F. | Journal of Clinical Oncology | 264 | 208 | |
2022 | Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors | Wu, Tsung-Che; CHIA-CHI LIN | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2 | | |
2016 | Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort | Chow L.Q.M.; Haddad R.; Gupta S.; Mahipal A.; Mehra R.; Tahara M.; Berger R.; Eder J.P.; Burtness B.; Lee S.-H.; Keam B.; Kang H.; Muro K.; Weiss J.; Geva R.; CHIA-CHI LIN ; Chung H.C.; Meister A.; Dolled-Filhart M.; Pathiraja K.; Cheng J.D.; Seiwert T.Y. | Journal of Clinical Oncology | 657 | 141 | |
2007 | Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial | CHIA-CHI LIN ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HSIN YANG | Investigational New Drugs | 104 | 103 | |
2023 | Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC | Zhou, Qing; Soo, Ross A; Chang, Gee-Chen; Chiu, Chao-Hua; Hayashi, Hidetoshi; Kim, Sang-We; Teraoka, Shunsuke; Goto, Yasushi; Zhou, Jianying; Ho-Fun Lee, Victor; Kim, Dong-Wan; Han, Baohui; Chung Man Ho, James; CHIA-CHI LIN ; Lu, Shun; Polli, Anna; Calella, Anna Maria; Martini, Jean-François; Wong, Chew Hooi; Mok, Tony; Kim, Hye Ryun; Wu, Yi-Long | JTO clinical and research reports | 3 | 0 | |
2020 | Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC | Tan W.L.; Chua K.L.M.; CHIA-CHI LIN ; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG ; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. | Journal of Thoracic Oncology | 32 | 30 | |
2020 | Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; Chia-Chi Hsu; BIN-CHI LIAO ; Wei-Hsun Hsu; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 55 | 49 | |
2009 | Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy | Feng-Ming Hsu ; Lee Y.-C.; JANG-MING LEE ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YU-CHIEH TSAI ; Wu J.-K.; CHIA-HSIEN CHENG | Annals of Surgical Oncology | 33 | 32 | |
2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; Liu, Yi-Nan; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; BIN-CHI LIAO ; Hsu, Chia-Chi; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | Oncologist | 15 | 15 | |
2009 | Atorvastatin induces thrombomodulin expression in the aorta of cholesterol-fed rabbits and in TNFα-treated human aortic endothelial cells | Lin S.-J.; Hsieh F.-Y.; Chen Y.-H.; CHIA-CHI LIN ; Kuan I.-I.; SHU-HUEI WANG ; CHAU-CHUNG WU ; Chien H.-F.; Lin F.-Y.; YUH-LIEN CHEN | Histology and Histopathology | 20 | 20 | |
2022 | B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | JHE-CYUAN GUO ; Hsu, Chia-Lang; YEN-LIN HUANG ; CHIA-CHI LIN ; TA-CHEN HUANG ; Wu, I-Chen; Lin, Chen-Yuan; Lien, Ming-Yu; HUNG-YANG KUO ; ANN-LII CHENG ; CHIH-HUNG HSU | Frontiers in oncology | 1 | 1 | |
2014 | Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer | JIH-HSIANG LEE ; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; YEUN-CHUNG CHANG ; CHONG-JEN YU ; JIN-YUAN SHIH ; CHIA-CHI LIN ; KUAN-YU CHEN ; CHAO-CHI HO ; WEI-YU LIAO ; PAN-CHYR YANG ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 44 | 35 | |
2018 | Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients | Wu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE ; CHIA-CHI LIN ; WEI-YU LIAO ; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG | Clinical Lung Cancer | 16 | 17 | |
2020 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial | Paz-Ares L.; Kim T.M.; Vicente D.; Felip E.; Lee D.H.; Lee K.H.; CHIA-CHI LIN ; Flor M.J.; Di Nicola M.; Alvarez R.M.; Dussault I.; Helwig C.; Ojalvo L.S.; Gulley J.L.; Cho B.C. | Journal of Thoracic Oncology | 112 | 101 | |
2021 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia | CHIA-CHI LIN ; Doi T.; Muro K.; Hou M.-M.; Esaki T.; Hara H.; Chung H.C.; Helwig C.; Dussault I.; Osada M.; Kondo S. | Targeted Oncology | 16 | 12 | |
2022 | Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial | Brose, Marcia S; Robinson, Bruce G; Sherman, Steven I; Jarzab, Barbara; CHIA-CHI LIN ; Vaisman, Fernanda; Hoff, Ana O; Hitre, Erika; Bowles, Daniel W; Sen, Suvajit; Oliver, Jennifer W; Banerjee, Kamalika; Keam, Bhumsuk; Capdevila, Jaume | Cancer | 11 | | |
2021 | Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial | Brose M.S.; Robinson B.; Sherman S.I.; Krajewska J.; CHIA-CHI LIN ; Vaisman F.; Hoff A.O.; Hitre E.; Bowles D.W.; Hernando J.; Faoro L.; Banerjee K.; Oliver J.W.; Keam B.; Capdevila J. | The Lancet Oncology | 111 | 101 | |
2013 | Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial | Smith D.C.; Smith M.R.; Sweeney C.; Elfiky A.A.; Logothetis C.; Corn P.G.; Vogelzang N.J.; Small E.J.; Harzstark A.L.; Gordon M.S.; Vaishampayan U.N.; Haas N.B.; Spira A.I.; Lara Jr. P.N.; CHIA-CHI LIN ; Srinivas S.; Sella A.; Sch?ffski P.; Scheffold C.; Weitzman A.L.; Hussain M. | Journal of Clinical Oncology | 374 | 346 | |